Trial Profile

Establish and Characterize an Acute HIV Infection Cohort in a High Risk Population

Status: Recruiting

Phase of Trial: Phase IV

Latest Information Update: 25 May 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dolutegravir (Primary) ; Efavirenz (Primary)
Indications HIV infections; HIV-1 infections
Focus Therapeutic Use

Most Recent Events

27 Apr 2026 Planned number of patients changed from 750 to 777.
27 Nov 2024 Planned number of patients changed from 724 to 750.
17 Oct 2023 Planned number of patients changed from 644 to 724.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com